{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:18:16Z","timestamp":1793441896316,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,22]],"date-time":"2027-10-22T00:00:00Z","timestamp":1824163200000},"content-version":"am","delay-in-days":263,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.bone.2026.118130","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:48:27Z","timestamp":1791560907000},"page":"118130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Predictors of the response to romosozumab in women with postmenopausal osteoporosis previously treated with denosumab"],"prefix":"10.1016","volume":"215","author":[{"given":"Kazuaki","family":"Mineta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Nishisho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sairyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.118130_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyp276","article-title":"Cohort profile: research on osteoarthritis\/osteoporosis against disability study","volume":"39","author":"Yoshimura","year":"2010","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.bone.2026.118130_bb0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s13018-021-02821-8","article-title":"Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.bone.2026.118130_bb0015","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2666-7568(21)00172-0","article-title":"Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the global burden of disease study 2019","volume":"2","year":"2021","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.bone.2026.118130_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10192","article-title":"Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States","volume":"3","author":"Lewiecki","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.118130_bb0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00198-004-1762-7","article-title":"Quality of life in patients with osteoporosis","volume":"16","author":"Lips","year":"2005","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0030","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2017.14484","article-title":"Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO\/ASCO","volume":"147","author":"Meier","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.bone.2026.118130_bb0035","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4158\/EP-2019-0596","article-title":"Anabolic therapy and optimal treatment sequences for patients with osteoporosis at high risk for fracture","volume":"26","author":"Cosman","year":"2020","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2026.118130_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 version","volume":"31","author":"Soen","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2026.118130_bb0050","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118130_bb0055","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.118130_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118130_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10637","article-title":"The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: a multicenter retrospective study","volume":"6","author":"Inose","year":"2022","journal-title":"JBMR. Plus."},{"key":"10.1016\/j.bone.2026.118130_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone. Reports."},{"key":"10.1016\/j.bone.2026.118130_bb0075","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","article-title":"Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study","volume":"32","author":"Tominaga","year":"2021","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0080","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00198-024-07155-9","article-title":"The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland","volume":"35","author":"Everts-Graber","year":"2024","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2026.117892","article-title":"The effect of prior osteoporosis treatment on bone mineral density response to romosozumab","volume":"209","author":"Ta","year":"2026","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118130_bb0090","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00198-025-07808-3","article-title":"A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis","volume":"37","author":"Richardson-Thornton","year":"2026","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0095","series-title":"Guideline for Prevention and Treatment of Osteoporosis 2015","author":"Japan Osteoporosis Society","year":"2015"},{"key":"10.1016\/j.bone.2026.118130_bb0100","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bone.2006.06.007","article-title":"Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis","volume":"39","author":"Gallagher","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118130_bb0105","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118130_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","article-title":"Application of a new serum assay for type 1 collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment","volume":"63","author":"Gerz","year":"1998","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.118130_bb0115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1570-0232(02)00431-2","article-title":"Acid phosphatase as markers of bone metabolism","volume":"781","author":"Igarashi","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.bone.2026.118130_bb0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","article-title":"Executive summary of the Japan osteoporosis society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 edition)","volume":"498","author":"Nishizawa","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bone.2026.118130_bb0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","article-title":"Baseline serum P1NP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis","volume":"34","author":"Kashii","year":"2023","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0130","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1080\/14397595.2019.1657653","article-title":"Establishment of anti-C1q monoclonal antibodies to measure serum C1q levels discriminating disease severity subsets of rheumatoid arthritis within 5 years of onset","volume":"30","author":"Yukioka","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bone.2026.118130_bb0135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely-available easy-to-use software \u2018EZR\u2019 (Easy R) for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bone.2026.118130_bb0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2026.118130_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117164","article-title":"Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: an observational study","volume":"186","author":"Mineta","year":"2024","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118130_bb0150","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.118130_bb0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118130_bb0160","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME study: the foundation effect of build ing bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118130_bb0165","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/jbmr\/zjae179","article-title":"Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women","volume":"40","author":"Hong","year":"2025","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118130_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal psteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2026.118130_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12\u202fmonths of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.118130_bb0180","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"20","author":"Kendler","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118130_bb0185","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118130_bb0190","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s00774-020-01126-w","article-title":"Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment","volume":"38","author":"Kondo","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2026.118130_bb0195","doi-asserted-by":"crossref","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","article-title":"Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion?","volume":"109","author":"Grassi","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118130_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116498","article-title":"Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting","volume":"163","author":"Everts-Graber","year":"2022","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822600356X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822600356X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:24:10Z","timestamp":1792682650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822600356X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":40,"alternative-id":["S875632822600356X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.118130","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of the response to romosozumab in women with postmenopausal osteoporosis previously treated with denosumab","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.118130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118130"}}